Articles related to Internal Medicine

Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial.

Although still a lower projection from a month ago, the University of Washington’s Institute for Health Metrics Evaluation (IHME) model increase is due to “many states experiencing flatter and thus longer epidemic peaks.” It also said that coronavirus deaths across the country are not falling “very quickly” after their estimated peak.

This feature article from the BMJ discusses how and why American oncologists are rushing to prioritize the patients at greatest risk, institute new protections, and learn from their collective experiences during the COVID-19 pandemic.

Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.

The Journal of Internal Medicine stresses that, although the timing of antiviral therapy may significantly slow COVID-19 progression, the study was underpowered to evaluate the therapeutic effect of the drugs and they should continue to be used only in studies, not empirical use.

A JAMA “Original Investigation” seeks to discover the characteristics, clinical presentation, and outcomes of 5,700 patients hospitalized with COVID-19 in the United States, specifically in the New York City area.